Fat Tissue’s Graft in Osteoarthritis Treatment: Indications, Preparations, and Results by De Fenu, Edoardo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Fat Tissue’s Graft in Osteoarthritis 
Treatment: Indications, 
Preparations, and Results
Edoardo De Fenu, Berardino Di Paola, Marco Ruggiero, 
Bruno Carlesimo, Andrea Conversi and Ezio Adriani
Abstract
Osteoarthritis (OA) represents one of the most common causes of joint pain and dis-
ability with related changes in bone morphology. In last years, this pathology is steadily 
increasing due to the continuous increase in the average life expectancy and the rate of 
active population. In recent years, there have been many conservative treatments for 
symptomatic gonarthrosis in order to reduce pain and delay or avoid the implantation of 
a knee prosthesis. The most studied and used was infiltrating treatment. Our group has 
been paying attention to regenerative medicine for many years, focusing on the charac-
teristics of adipose tissue and the presence of multipotent mesenchymal cells, particu-
larly in the vascular stromal area. Mesenchymal stem cells (MSCs) of adipose tissue can 
commit toward the chondrogenic, osteogenic, adipogenic, myogenic, and neurogenic 
lineages. Our group has continued the studies in this field by submitting this to treat-
ment patients with grade II–III arthrosis according to the scale of Kellgren-Lawrence 
or patients with IV degree of such scale inoperable for internal reasons. To date, with a 
4-year follow-up, our results are satisfactory in terms of pain reduction, improvement in 
joint function, and recovery of daily and sports activities.
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1. Introduction
Osteoarthritis is a common degenerative joint cartilage disorder associated with 
hypertrophic bone changes and loss of joint cartilage integrity [1]. It causes pain, 
stiffness, and reduction of the associated function, consequently, disability with 
relative difficulty for the patient in carrying out the normal daily activities [2]. 
Risk factors are represented by genetic factors, female sex, post-traumatic condi-
tions, age, obesity, etc. [3–6]. Treatment is therefore aimed at reducing symptoms, 
improving quality of life, and preventing its progression. Treatment options can be 
classified into:
• Conservative treatment, such as lifestyle education, pain therapy and physio-
therapy, and infiltrative therapy.
• Surgical treatment, traditionally represented by arthroplasty and osteotomy 
and in some cases by arthroshaving [2].
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Several national and international OA management guidelines recommend that 
patients should be first introduced into pathways that provide conservative treat-
ment options and then directed to surgical treatment only when the conservative 
treatment does not allow the desired therapeutic achievement [7–10].
2. Epidemiology and causes
It represents the most common joint disease in the world, even if the frequencies 
vary from country to country: it affects more than 40 million individuals only in the 
United States and about 4 million in Italy, thus representing the main cause of dis-
ability at a national level. Therefore, OA is responsible for direct and indirect medi-
cal costs for society: clinical visits by primary care physicians or specialists, drugs, 
and surgical interventions represent direct costs; comorbidity and time lost from 
work due to the effects of disability are the examples of indirect costs. This clinical 
condition is more evident among the elderly, who may lose their independence and 
then need assistance during their daily activities, thus increasing the economic 
burden [11–13]. The lifetime risk of developing symptomatic osteoarthritis of the 
hip is 18.5% for men and 28.6% for women. For symptomatic knee OA, it is around 
45%. Therefore, the risk of being subjected to a total hip or knee prosthesis at the 
age of 50 results to be high, with values of 7.1–11.6% for the hip and 8.1–10.8% for 
the knee [14, 15].
OA has a multifactorial etiology, and it is a disease that affects not only the qual-
ity of all synovial joint structures but also the function and quality of surrounding 
tissues and the pathway of nociceptive signaling. The causes that lead to the onset 
of osteoarthritis are largely unknown. On the other hand, it is believed that in most 
cases, many factors that alter the joint balance are involved. Schematically, the 
joint balance can be maintained if a normal load is exerted on a normal cartilage. 
Therefore, all factors capable of modifying this balance, acting either on the load 
or modifying the characteristics of cartilage, can be considered risk factors for 
osteoarthritis. In most cases, there is a combination between the genetic predisposi-
tion of the individual and the influence of environmental factors, especially those 
that act on the load, such as mechanical stress, obesity, malformations, trauma, and 
microtrauma. The precocity of the onset and the type of evolution may then depend 
on the number of factors involved, on their size and on the duration of their action. 
The OA can be divided into primary and secondary forms. The primary form, or 
idiopathic, manifests itself in intact joints without any triggering factor. Aging plays 
a fundamental role in this form of OA: the joint wear causes damage to the cartilage 
and, associated with an abnormal repair mechanism, the disease manifests itself. In 
the secondary form, OA is caused by a predisposing factor. In general, any violation 
of the integrity of the chondrocyte matrix has the potential to cause OA. However, 
some considerations aside highlight age as a risk factor. Although we all know that 
the frequency of arthrosis increases with age, arthritis is currently considered not 
to be a disease of aging. In fact, not all the elderly has this disease. It is therefore 
probable that the genetic tendency that an individual has in the predisposition 
to contract sooner or later some diseases, including arthritis, can be accentuated 
and accelerated by the risk factors. Obviously, among the elderly, the duration of 
exposure to these risk factors is higher, so the consequences are more evident.
Some risk factors are not changeable, such as age and genetic predisposition, 
while others, such as mechanical ones, overweight, etc., are considered modifiable 
and therefore, a rarely feasible consideration for other rheumatic diseases [16, 17].
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Attention must also be given to another attachment of the joints overlapping the 
OA for clinical and disability: osteonecrosis. Osteonecrosis is estimated to be the 
cause of 10% of all total hip arthroplasty performed in the United States.
However, differentiation between these conditions can be difficult, particularly 
at the beginning of the pathological process [18, 19].
It is a disease characterized by the interruption of the normal supply of bone 
blood resulting in “death” bone. At this point, the healing response may be 
inadequate and then the joint surface collapses with the subsequent degenerative 
arthritis [18].
Osteonecrosis is more common in patients under the age of 40 and has no sexual 
preference. Among the risk factors acquired for osteonecrosis, alcohol abuse, 
smoking, and trauma are more common in men, while rheumatic diseases, such as 
systemic lupus erythematosus, are more commonly found in women. Therefore, 
the predilection of sex in osteonecrosis is highly influenced by the associated risk 
factors [20].
OA develops with the combination of biochemical, cellular, and mechanical 
processes [21].
OA is associated with biochemical events mediated by cytokines, proteolytic 
enzymes, and other proinflammatory substances responsible for osteolysis, 
subchondral bone sclerosis, osteophytosis, articular erosion of the cartilage, and 
thickening of the synovial membrane [22, 23].
Following the break of the cartilaginous matrix, due to proteolysis, the cartilage 
weakens and becomes subject to fibrillation and erosion, resulting in the release of 
proteoglycans and collagen fragments in the synovial fluid. This process induces 
an inflammatory response in the synovium, which causes further degradation of 
the cartilage. When the cartilage weakens, it begins to thin out, causing a reduction 
in joint space. Cartilage damage also causes the appearance of periarticular osteo-
phytes. The exact mechanism of pain generation in OA is not well understood, but is 
probably related to an interaction of different mechanisms [21, 24].
From a purely biochemical point of view, OA is the result of an imbalance 
between the peptides that promote the synthesis of components of the ECM (extra-
cellular matrix) of the articular cartilage and those that induce the remodeling of 
these components. [25–31].
The result of these catabolic cascades is the persistence of the synovitis, with initial 
cartilage damage and induction of remodeling of the subchondral bone [32, 33]. 
The pathogenesis of OA is therefore composed of a network of overlapping complex 
molecular mechanisms, which entail damage to the articular tissue. These mecha-
nisms depend on the equilibrium of expression of the catabolic and anabolic articular 
molecules.
3. Therapy
The goals of therapy in OA can be defined as “short-term,” represented by pain 
control, stiffness control, and reduction of inflammation and “medium-long term,” 
represented by the arrest or slowing of progression, by deformity prevention, and 
restoration of function.
For the pursuit of these objectives, many strategies can be used, both pharma-
cological and nonpharmacological, which often need to be coordinated with each 
other to be really effective. In fact, in addition to the introduction of new drug 
therapies, the importance of general measures, such as patient education to the 
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knowledge of the disease and the consequent implementation of some measures 
such as weight loss and gymnastics or the use of unloading orthoses is recom-
mended [10, 34, 35].
For conservative treatment, today we have several strategies available that, as 
mentioned, where possible, must be evaluated and taken into account in relation to 
the clinical condition of the patient.
An increasingly important role in the conservative treatment of OA is repre-
sented by the infiltrative therapy that in recent years has proposed a wider range of 
solutions: from intra-articular anti-inflammatory therapy as a palliative treatment 
to an infiltrative solution that can restore joint homeostasis or that can possibly 
activate a regenerative process into the joint.
Intra-articular corticosteroid injections may be indicated after failing NSAIDs 
and acetaminophen, but some researchers suggest only using them once every 3 
months for a maximum of 2 years due to negative potential side effects [36].
The mechanism underlying the anti-inflammatory efficacy of corticosteroid 
is multifactorial, but generally involves blocking antigen opsonization, leuko-
cytic cell adhesion, and cytokine diapedesis within the capillary endothelium. 
Corticosteroids also attenuate the effects of IL-1, decrease leukotriene and prosta-
glandin release, and inhibit metalloproteases and immunoglobulin synthesis [37].
The duration of action of intra-articular corticosteroid injections remains 
 controversial, with various studies quoting anywhere between 1 and 24 weeks. 
There is consensus that steroids provide relief to patients for approximately 1 week 
after injection.
Adverse effects of corticosteroid injections do exist; however, Handler and 
Wright first described radiographic evidence of destruction of the knee joint and 
cartilage after several corticosteroid injections [38]. The incidence of joint infec-
tion following corticosteroid administration is rare, but may be as high as one in 
3000 patients, with an associated mortality rate of approximately 11%. Additional 
known complications include pain, skin atrophy, tendinopathy, and systemic 
hyperglycemia [39].
The use of this procedure results in an inconclusive recommendation strength [10].
4. Hyaluronic acid injections
HA plays a fundamental role in maintaining elasticity and viscosity of the 
synovial fluid and integrity of the connective tissues such as joints [40, 41]. Several 
studies have shown that HA is a chondroprotector: it synthesizes proteoglycan and 
glycosaminoglycan, and it has anti-inflammatory, mechanical, subchondral, and 
analgesic actions [40].
5. Platelet-rich plasma
Platelet-rich plasma (PRP) is the most investigated biological treatments 
[42–44] due to the capacity to reduce inflammation and consequently a reduction 
of pain [45–47]. PRP exerts its biological effect with neoangiogenesis and migration 
of macrophages and mesenchymal cells and regulates cell differentiation and the 
activity of different cell lines, promoting tissue regeneration. PRP is controversial 
for the treatment of OA, because there is insufficient evidence to recommend the 
use of it [48–50].
Despite the growing interest in this biological approach for cartilage regenera-
tion, the knowledge on this topic is still preliminary [51].
5Fat Tissue’s Graft in Osteoarthritis Treatment: Indications, Preparations, and Results
DOI: http://dx.doi.org/10.5772/intechopen.82566
6. Biological use of fat tissue
The promise of mesenchymal stem cells (MSCs) to give birth to a new era of 
medicine was strong, thanks to the ability of these cells to do self-renewal and mul-
tipotent in vitro differentiation into mesodermal cell subtypes. To be honest, recent 
studies have demonstrated that a good portion of the thrilling in vivo clinical results 
is due to the trophic, paracrine, and immunomodulatory activities of MSCs instead 
of their differentiation ability [52]. Differently from drug concept where the effect 
is dependent from concentration, MSCs are self- and site-regulated and they release 
a multitude of bioactive factors in variable concentration in response to the local 
messages of the microenviroment. The main trophic activity exerted by MSCs is the 
release of growth factors and other chemokines to induce the homing and prolifera-
tion of cellular progenitors and to promote angiogenesis. These factors are transform-
ing growth factor beta (TGF-β), hepatocyte growth factor (HGF), endothelial growth 
factor (EGF), fibroblast growth factor 2 (FGF-2), and insulin-like growth factor 1 
(IGF-1)—all of these are proteins able to accelerate cellular growth and division of 
progenitors [53]. Moreover, IGF-1, EGF, and the vascular endothelial growth factor 
(VEGF) are able to recruit endothelial cells and promote new vascularization [54].
MSCs can derive from many tissue sources, and among these, the more manage-
able for clinical practice is bone marrow and adipose tissue. Even if the MSCs from 
bone marrow (BM-MSCs) were discovered first and have more clinical experience, 
there is higher interest on adipose tissue—not only for the ease and low morbidity of 
harvest but also because it has a higher MSCs frequency. In a bone marrow aspirate, 
there are 6 × 106/ml nucleated cells and, among these, only 0.001–0.01% are MSCs; 
on the other hand, a lipoaspirate contains 0.5–2.0 × 106/g nucleated cells where the 
MSCs frequency ranges from 1 to 10% based on the donor site. Since the adipose tis-
sue has a total of 0.5 × 104–2 × 105/g of MSCs, it means that there is a 500-fold higher 
concentration of MSCs in comparison with bone marrow [55]. Moreover, it has been 
demonstrated that the proliferation and differentiation properties of stem cells from 
adipose tissue (ADSCs) are less impaired by age in comparison with BM-MSCs [56].
ADSCs can be exploited with three different methods. The first, the only option 
where we can properly name them as true ADSCs, is the cell culture and optional 
cell expansion in vitro. By selecting the cells that are able to stick to the plastic, it 
is possible to obtain cell that expresses mesenchymal markers (CD105+, CD73+, 
CD90+, CD45−, CD34−, CD11b−, CD14−, CD79a−, and HLA-DR−) able to dif-
ferentiate into the three mesodermal lineages (bone, cartilage, and fat). This option 
has serious limitation in the clinical practice due to regulatory issues because it can 
only be performed into good manufacturing practice facilities that manipulate these 
cells like an experimental drug (it is named advanced cellular therapy). Notably, 
concentrated BM-MSCs outperform cultured cells since they are more practical 
and efficient and less harmful and expensive [52]. The second method is enzymatic 
digestion of adipose tissue that gives in the hands of operators a heterogeneous cell 
population that contains, beside MSCs, endothelial cells, leucocytes, and preadipo-
cytes. This final product of enzymatic digestion is named stromal vascular-fraction 
(SVF). Finally, autologous ADSCs can be exploited through the processing and 
fragmentation of adipose tissue (FAT, fragmented adipose tissue). While the SVF is 
a heterogeneous cell population where each cell is separated from the others and 
the efficacy is dose-dependent, the FAT is a proper minimally manipulated tissue 
that entrust more on cell quality instead of cell quantity. The FAT is composed of 
tissue cluster of variable diameter where the SVF cells are embedded and attached 
to an undisrupted tissue architecture made of vasculature and extracellular matrix 
sustained by a scaffold made of adipocytes. This natural scaffold protects cells from 
anoikis (death cause by the lack of cellular adherence) and other harmful stress. 
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The MSCs embedded into these clusters have high vitality and can still differentiate 
into the three mesodermal lineages as a proof of their multipotency. To prove that 
quality is superior to quantity, it has been demonstrated in an animal model of criti-
cal limb ischemia that an injection of 500 μl of FAT (which contain 2 × 104 ADSC) 
restores limb perfusion better than a single injection of 1 × 106 isolated ADSC [57].
During the First World War, the fat was used to heal soldier wounds and its 
application was very heterogeneous until 1990 where Sidney Coleman defined 
precise guidelines. The evolution of surgical techniques associated the volumizing 
effect of lipofilling to the regenerative properties of natural adipose tissue, favoring 
the processing, the reduction, and the purification of the tissue to raise the survival 
of grafts and magnify the regenerative potential of MSCs. Also reducing the volume 
of grafts and the diameter of injection needles had helped the hosting tissue to 
decrease stress and trauma, thus provoking less inflammation and ameliorating again 
graft survival [58]. Adipose tissue is now used with lipofilling techniques in hard-to-
heal wounds and in all cases characterized by mortified tissue (burn, compression, 
and radiation) linking the regenerative potential also to an esthetic effect. Wound 
healing professionals use lipofilling to treat ulcers resistant to classical therapies and 
advanced dressing and also for the treatment of critical limb ischemia and diabetic 
patients [59]. In orthopedics, intra-articular lipofilling has become a fashionable and 
innovative strategy to fight osteoarthritis, thanks to the ability of this tissue product 
to reequilibrate the articular homeostasis and to reduce the inflammation of the 
synovial membrane [60]. The integrity of the extracellular matrix can also exploit 
the shock absorber function of adipose tissue reducing the stress between cartilage 
surfaces. The paracrine effect of MSCs can also promote cartilage repair when 
mechanical conditions of the articulation are stable. The anti-adhesive properties of 
adipose tissue were exploited in the surgery of tendons and nerves to limit the forma-
tion of fibrotic and scarring tissue, thus also limiting the relapse incidence. Finally, 
adipose tissue was also studied in pain management for the intradiscal infiltration for 
the treatment of low back pain associated to black disc.
7. Lipofilling
The technique of liposculture is originally created for esthetic purposes. 
Autologous fat transfer has recently become an increasingly popular surgical 
procedure: harvesting, refinement/processing, and transfer of subcutaneous tissue 
to provide relatively pure and intact parcels of fat are paramount for successful 
lipofilling. Usually, we use local anesthesia with sedation or epidural anesthesia. 
Rarely, we use general anesthesia.
• Incisions with a n°11 blade are made in the donor site. When possible, incisions 
are placed in wrinkle lines, folds, or fatty areas (abdomen flank, thigh, and 
knee).
Instruments for lipofilling cause minimal trauma to fatty tissue during placement.
• Cannulas vary in shape (curved or no-curved) and length (7–12 cm).
Liposuction: special blunt-tip, maximum diameter 3 mm, with small holes near 
the tip
 ○ Coleman I is used near a blood vessels or nerve. This cannula is capped on the 
tip with a lip that extends 180° over the distal aperture.
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 ○ Coleman II is used in other circumstances. This cannula is not completely 
capped and has a lip that extends over the distal aperture about 130–150°.
 ○ Coleman III is used for the scars or fibrous tissue treatments. This cannula is 
flat on the end to allow for dissection of the tissue.
 ○ Coleman V is a dissector used for scar’s treatment.
Transplantation: small blunt-tip
 ○ Infiltration cannula is a blunt 17G cannula with one or two distal aperture 
proximal to the tip: no fatty tissue should be infiltrated during the advance-
ment of the cannula; fatty tissue is left in the pathway of the retreating blunt 
cannula (this method permits stable and regulated placement with minimal 
irregularities or clumps of tissue).
8. Surgical technique
8.1 Harvesting of adipose tissue from a suitable donor site
Many different techniques have been proposed for harvesting of adipose tissue: 
the fundamental aim is minimizing adipocyte damage and increasing the survival 
of adipose tissue. Incisions with a n°11 blade are made in the donor site, when pos-
sible in wrinkle lines, folds, or fatty areas (abdomen, flank, thigh, and knee).
There are many different natural fat deposits: it is important an accurate preop-
erative examination of the patient.
The abdomen is the most common site of fat harvesting; it is also common in the tro-
chanteric region (saddlebags) and in the medial/internal part of the thighs and knees.
The main techniques for fat harvesting are vacuum suction, syringe suction, or 
surgical excision.
8.1.1 DRY technique
Other surgeons advocate a “dry” fat harvesting: cell viability has been similar to “wet” 
fat harvesting nut, and this technique may lead to a greater requirement for analgesic.
8.1.2 WET technique
In 1993, Klein proposed a new method called tumescent technique in which 
a fluid solution (Klein’s solution) was injected into the donor site improving the 
safety of large-volume liposuction (it eliminated the need for general anesthesia 
and reduced surgical hemorrhage).
Another technique is the “Berlin autologous lipotransplantation”, which involves 
the use of a water-jet system to harvest the fat tissue and collect it in a closed 
container: minimal bruising and postoperative pain, faster harvesting time, and 
greater sterility.
In the course of fat harvesting, a blunt cannula is inserted through an incision 
into fatty tissue engorged with tumescent fluid (Klein’s solution)
• Negative pressure liposuction is faster than 10 ml syringe aspiration (low pres-
sure) and is an effective method for aspiration of large amounts of fat, but it causes 
massive destruction of adipocytes, greatly reducing the survival of fat graft.
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• Conventional liposuction with high negative pressure may cause disruption of 
90% of adipocytes structures.
Cannula size may also impact the viability of harvested adipocytes. Performing 
biopsy and lipoaspiration with large-bore cannulas could reduce the risk of cellular 
rupture by preserving native tissue structure.
So the size of cannula must be large enough to preserve adipocytes and stromal 
cells and their anatomical relationship without limiting diffusion of nutrients.
Coleman described a technique for fat harvest that minimized trauma to the 
adipocytes.
He used 3-mm incisions (n°11 blade), a 3-mm blunt edge, 2 hole harvesting 
cannulas (3 mm) connected to a 10-ml Luer-Lock syringe. The cannula is pushed 
through the harvest site (abdomen, flank, thigh, knee, or other sites with excess 
adipose tissue) as the surgeon uses digital manipulation to create a gentle negative 
pressure.
A combination of lower negative pressure and the curetting action of the can-
nula through the tissues allows parcels of fat to move into the syringe. At the end, 
the syringe is disconnected from the cannula and replaced with a plug that seals the 
Luer-Lock end of the syringe.
8.2 Processing
The most commonly used methods to process fat tissue are centrifugation, sedi-
mentation, washing, and filtration. Comparative studies investigating the effects of 
fat processing with different techniques have showed no significant differences in 
fat retention.
The goal of fat processing is:
To eliminate contaminants that can cause inflammation at the recipient site, 
which can be detrimental for the fat graft. These elements include cellular debris, 
free oil, and other nonviable components of the lipoaspirate such as hematogenous 
cells.
• Blood must be extracted in order to improve degradation of the transplanted 
fat.
• Since the debris will be absorbed after a few hours, its injection could be 
confused with volume correction.
• Moreover, many authors report an improvement in graft viability by maximiz-
ing the number of ADSC in the graft material.
8.3 Ensuring graft viability
Centrifugation is the most widely used technique for postharvest fat processing 
and has previously been considered the criterion standard. Coleman’s technique 
consisted in centrifugation (3000 rpm for 3 minutes) to separate the different 
components as follows:
• Upper level: least dense and consists primarily of oil.
• Middle: primarily fatty tissue.
• Lowest: blood, water, and aqueous elements.
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The supernatant fat and the lower aqueous layers are discarded, leaving concen-
trated viable fat cells.
That is an optimal method to obtain the highest concentration of stem cells and 
increased angiogenic grow factors (FGF and VEGF). It separates adipocytes from 
blood cells and enzymes (lipids, proteases, and lipases). Sedimentation allows 
obtaining a large number of vital intact adipocytes [61].
Washing methods has the goal of removing superfluous tumescent fluid and all 
elements that can be detrimental for the fat graft.
• Lipocell technique is a new procedure that allows eliminating blood, oil, cel-
lular debris, or other nonviable components and obtaining a pure lipoaspirate. 
This technique preserves a large number of mesenchymal stem cells and a large 
number of adipocytes.
Filtration allows elimination of contaminants by maintaining viable adipocytes and 
a lot of ADSC, thus obtaining a viable graft material for large volume fat transfers.
• Pure graft filtration is a new technology that uses a closed-membrane filtra-
tion system for preparation and isolation of stromal vascular fraction and its 
mechanism is known to work by principles similar to a dialysis unit.
8.4 Implantation/fat injection
Principles of fat reimplantation are found on optimal recipient site vascularity to 
increas fat survival.
Graft can survive up to 48 hours by tissue fluid absorption.
Neovascularization progresses 1 mm/day; therefore, a deposit diameter greater 
than 2 mm should be avoided to prevent central necrosis. With a skin incision like a 
diameter of the cannula, the graft is put at the level of the anatomical region involved. 
Cannulas with small gauge will reduce tissue trauma, bleeding, and hematoma.
Through multiple access sites, multiple tunnels are created on insertion, but fat 
is injected only during withdrawal of the cannula.
In our experience, mainly concentrated on the knee involves the constant asso-
ciation of a diagnostic and surgical arthroscopy; in fact, in the majority of cases, 
there are meniscal lesions (flap type) or unstable chondral lesions which, if left 
untreated, could lead to failure of the grafting procedure alone.
9. Complications
All steps in surgical technique (harvesting, processing, and transplantation) are 
important. Complications are few, rare, and minimal. Viability of fat cells is crucial. 
The chances of survival are higher if the fat graft is less manipulated and reinjected 
as fast as possible.
• Donor site complications related to lipoaspirate technique: bruising, swelling, 
hematoma, pain, paresthesia, infection, pathologic scarring, contour irregu-
larities, cellulitis, and damage to the underlying structures.
• Failure of fat graft in recipient sites could cause fat necrosis, oil cysts, calcifica-
tions, reabsorption of fat, and intravascular injection with fat embolism.
Early identification of local sepsis.
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10. Conclusion
In conclusion, there are several treatments for knee OA including nonpharmaco-
logical and pharmacological treatments.
Among the nonpharmacological ones, patient education and self-management 
strategies, advising weight loss and strengthening programs are included.
Regarding the pharmacological treatment, the NSAIDs can be used in the short-
term therapy but their effect is limited in time.
Another employed strategy to manage knee OA is represented by joint injections 
of corticosteroids, hyaluronic acid, PRP, and even stem cells [47].
The reason for using ASCs in orthopedics is derived from tissue engineering 
studies that enhance their ability to differentiate into osteoblastic or chondrocyte 
using appropriate culture media and bioengineered structures that can accommo-
date cells as a biological scaffold.
The studies of Hattori and colleagues showed an osteogenic differentiation 
(by electron microscope, with histological evaluation and by the capacity of 
osteocalcin secretion) analogous to BMSC using a beta-tricalciophosphate scaf-
fold [62, 63].
Always Hattori and colleagues in 2008 proposed new strategies for the 
in vitro expansion of ASCs. In most cases, the expansion was obtained with 
fetal bovine serum (FBS) which, in subsequent clinical applications, could have 
caused infections or immunological reactions caused by the proteins present in 
the FBS [64].
For this reason, Hattori and colleagues have demonstrated, with studies on 
the mouse, that it is possible to obtain the expansion of the ASC with the same 
differentiation potentials, using a small amount of autologous serum contain-
ing type I, FGF-2 collagen and thus opening the way to possible therapeutic 
applications.
Promising is the application in the treatment of cartilaginous lesions. In 
2007, Masuoka and colleagues used a three-dimensional honeycomb scaf-
fold of atelocollagene (ACHMS scaffold) with ASCs for cartilaginous lesions 
in rabbit’s knees; as a control group, they used the only ACHMS-scaffold or 
nothing [65]. Twelve weeks later, histological analyzes have highlighted that 
only in cases where ASC + ACHMS-scaffold had been used, there was hyaline 
cartilage with high expression of type II collagen. It should be also noted that 
the ASCs, as mentioned above, have the ability to release factors of tissue 
growth and/or regeneration and cytokines. These substances play an important 
role in chemotaxis, in promoting tissue regeneration, cell differentiation, and 
neoangiogenesis.
Regenerative medicine opens the way for a new therapeutic frontier, as it now 
allows an improvement in symptoms and in the functionality of the joints. On the 
other hand, further studies are needed, major follow-ups, targeted clinical trials, 
and finally the possibility of a second look to evaluate and validate the real regen-
erative capacity of this treatment.
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